Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 20, 2024
Daily News
September 20, 2024
- Panelists See Legal Issue over Providers’ Refusal of People Vaccinated with Replicon Shot
September 20, 2024
- MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
- Early Use of High-Dose Mecobalamin Extends Survival in ALS: IIT Data
September 20, 2024
- 3 More Generic Firms Start Voluntary Recalls of Atomoxetine Products
September 20, 2024
- Xofluza Cuts Risk of Flu Transmission in Households: PIII Data
September 20, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…